Case study research allows for the identification of causal mechanisms underlying complex, systems-dependent phenomena-like innovation. However, determining that there is a causal effect does not provide the causal story.
Data governance in support of LHS initiatives for precision oncology implicates an intricate web of statutes, regulations, guidance, policies, and practices.
Precision oncology is premised on large-scale, annotated 'omics data that improve our understanding of mutations, treatment response, resistance, quality of life and side effects, within an LHS.
Confronted with value uncertainty and high patient demand, payers are considering managed access approaches that re-evaluate adopted technologies or that manage the risk of early patient access through risk-sharing arrangements between developers and healthcare systems.
Patients with advanced Hodgkin’s Lymphoma (HL) have been with the combination of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and have largely positive outcomes.
Stereotactic ablative radiotherapy (SABR) may offer potential benefit for patients with oligometastatic cancers. The SABR technology is still evolving, and there is still uncertainty about whether or not this treatment will be effective.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.